Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, Furukawa M, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG). Ozaka M, et al. Eur J Cancer. 2023 Mar;181:135-144. doi: 10.1016/j.ejca.2022.12.014. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36652891 Free article. Clinical Trial.
Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy.
Shibagaki K, Fujita K, Nakayama S, Takenaka M, Fukuba N, Matsui S, Ozaka M, Yoshinaga H, Masuzawa A, Watanabe A, Fujiwara H, Sugawara A, Fujita T, Mukai H, Kinoshita Y. Shibagaki K, et al. Among authors: ozaka m. Int J Clin Oncol. 2008 Feb;13(1):74-7. doi: 10.1007/s10147-007-0690-x. Epub 2008 Feb 29. Int J Clin Oncol. 2008. PMID: 18307024
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T. Ozaka M, et al. Cancer Chemother Pharmacol. 2012 May;69(5):1197-204. doi: 10.1007/s00280-012-1822-1. Epub 2012 Jan 17. Cancer Chemother Pharmacol. 2012. PMID: 22249272 Clinical Trial.
Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan.
Yamada I, Matsuyama M, Ozaka M, Inoue D, Muramatsu Y, Ishii H, Junko U, Ueno M, Egawa N, Nakao H, Mori M, Matsuo K, Nishiyama T, Ohkawa S, Hosono S, Wakai K, Nakamura K, Tamakoshi A, Kuruma S, Nojima M, Takahashi M, Shimada K, Yagyu K, Kikuchi S, Lin Y. Yamada I, et al. Among authors: ozaka m. Asian Pac J Cancer Prev. 2014;15(1):391-5. doi: 10.7314/apjcp.2014.15.1.391. Asian Pac J Cancer Prev. 2014. PMID: 24528063 Free article.
Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H, Ishii H, Nakai Y, Ozaka M, Ikari T, Koike K, Ueno H, Ioka T, Satoi S, Sho M, Okusaka T, Tanaka M, Shimokawa T, Kwon AH, Isayama H. Yanagimoto H, et al. Among authors: ozaka m. J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):761-6. doi: 10.1002/jhbp.130. Epub 2014 Jun 13. J Hepatobiliary Pancreat Sci. 2014. PMID: 24925464 Clinical Trial.
151 results